York, United Kingdom
Kirkstall Ltd, founded in 2006, is a biotechnology company known for creating the Quasi Vivo® system, a user-friendly, commercially available interconnected flow system tailored for the Biopharma, Biotechnology, and Pharmaceutical sectors.
Headquartered in the United Kingdom, Kirkstall has positioned itself as a pioneering entity in advancing laboratory methodologies, particularly for simulating real-life biological conditions. By addressing the growing need for more precise pharmacological research tools, Kirkstall offers solutions that facilitate improved drug discovery and testing.
Since its last investment round in July 2016, when it secured £250.00K from the Venture Round, spearheaded by Braveheart Investment Group, Kirkstall has piqued interest due to its innovative product offerings. Investors may find value in Kirkstall’s growth potential within the dynamic life sciences field, given its established longevity and niche market presence.
